BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 23108893)

  • 1. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination.
    Wu XJ; Yuan P; Li ZY; Bu ZD; Zhang LH; Wu AW; Zong XL; Li SX; Shan F; Ji X; Ren H; Ji JF
    Tumour Biol; 2013 Feb; 34(1):463-9. PubMed ID: 23108893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
    Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
    Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
    BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
    Yang XJ; Huang CQ; Suo T; Mei LJ; Yang GL; Cheng FL; Zhou YF; Xiong B; Yonemura Y; Li Y
    Ann Surg Oncol; 2011 Jun; 18(6):1575-81. PubMed ID: 21431408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination from Small Bowel Malignancy: Results from a Single Specialized Center.
    Liu Y; Ishibashi H; Takeshita K; Mizumoto A; Hirano M; Sako S; Takegawa S; Takao N; Ichinose M; Yonemura Y
    Ann Surg Oncol; 2016 May; 23(5):1625-31. PubMed ID: 26717938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
    Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J
    Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
    Canbay E; Mizumoto A; Ichinose M; Ishibashi H; Sako S; Hirano M; Takao N; Yonemura Y
    Ann Surg Oncol; 2014 Apr; 21(4):1147-52. PubMed ID: 24356799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
    Chia CS; You B; Decullier E; Vaudoyer D; Lorimier G; Abboud K; Bereder JM; Arvieux C; Boschetti G; Glehen O;
    Ann Surg Oncol; 2016 Jun; 23(6):1971-9. PubMed ID: 26753751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?
    Hotopp T
    Surg Oncol; 2019 Mar; 28():159-166. PubMed ID: 30851894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
    Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
    Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments.
    Santullo F; Ferracci F; Abatini C; Halabieh MAE; Lodoli C; D'Annibale G; Di Cesare L; D'Agostino L; Pecere S; Di Giorgio A; Strippoli A; Pacelli F
    Langenbecks Arch Surg; 2023 Nov; 408(1):437. PubMed ID: 37973620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
    Rudloff U; Langan RC; Mullinax JE; Beane JD; Steinberg SM; Beresnev T; Webb CC; Walker M; Toomey MA; Schrump D; Pandalai P; Stojadinovic A; Avital I
    J Surg Oncol; 2014 Sep; 110(3):275-84. PubMed ID: 25042700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study.
    Tang L; Mei LJ; Yang XJ; Huang CQ; Zhou YF; Yonemura Y; Li Y
    J Transl Med; 2011 May; 9():53. PubMed ID: 21548973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
    Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
    Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.